The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

CD30-directed Antibody-Glucuronide TOP1 Inhibitor Conjugate

Back

Molecule overview Clinical trials

CD30-directed Antibody-Glucuronide TOP1 Inhibitor Conjugate

PF-08046044, SGN-35C is an investigational compound. Its safety and efficacy have not been established

Share to an HCP

Overview + Rationale Mechanism of Action Stage of Development

Share to an HCP

Overview + Rationale

PF-08046044; SGN-35C is a CD30-directed ADC with the same mAb backbone as BV, conjugated to a novel TOP1 inhibitor through an enzyme-cleavable glucuronide linker.¹
CD30 is expressed in many B- and T-cell lymphomas while having limited expression in normal tissue²

Mechanism of Action

Stage of Development

R/R CD30-Expressing Lymphomas

Phase 1 Monotherapy

CD30-directed Antibody-Glucuronide TOP1 Inhibitor Conjugate

Geo Regions

CD30-directed Antibody-Glucuronide TOP1 Inhibitor Conjugate

Overview + Rationale

Mechanism of Action

Stage of Development

This information is current as of October 30th 2024.